Noninfectious and Nonneoplastic Conditions Associated with Human Immunodeficiency Virus Infection

M. Patricia George; Vikas Singh; Mark T. Gladwin

doi:10.1055/s-0036-1572560

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2016; 37(02): 289-302
DOI: 10.1055/s-0036-1572560

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Noninfectious and Nonneoplastic Conditions Associated with Human Immunodeficiency Virus Infection

Autoren

M. Patricia George

¹Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Vikas Singh

²Department of Medicine, UPMC East, Monroeville, Pennsylvania
Mark T. Gladwin

¹Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Abstract

The goal of this review is to describe evolving epidemiology of noninfectious, nonneoplastic pulmonary complications of HIV infection, including HIV-associated pulmonary arterial hypertension (HIV-PAH) and interstitial lung disease (ILD). The development of antiretroviral therapy has rendered HIV a chronic illness in treated patients, and the landscape of HIV-associated medical conditions continues to evolve. Although there has been a shift away from AIDS-defining infectious diseases and malignancies, HIV-PAH continues to affect survival adversely when compared with HIV-infected patients without PAH. Studies of pre- and post-highly active antiretroviral therapy (HAART) era show that the prevalence of HIV-PAH remains high and unchanged. The increased prevalence of PAH among HIV-infected individuals has led to several complementary theories about potential mechanisms underlying this disease. Unique mechanisms of HIV-PAH focus on direct effects of viral proteins; alterations in cellular immunologic/inflammatory reactions to the virus; additive effects of cocaine, heroin, and other drugs of abuse; and potentially toxic aspects of antiretroviral and associated therapies. PAH-specific therapy with HAART is likely beneficial in the treatment of HIV-PAH patients. The prevalence of ILD in HIV-infected individuals is also significantly higher than that in the general population. Lymphoid interstitial pneumonitis (LIP) and nonspecific interstitial pneumonia (NSIP) have been reported in both HIV-infected children and adults, and NSIP is more common than LIP in HIV-infected patients. At present, there is no consensus on the pathogenesis of LIP and NSIP in HIV. Finally, we briefly review the literature on venous thromboembolic disease in HIV-infected individuals.

Keywords

HIV-associated pulmonary hypertension - pulmonary arterial hypertension - lymphoid interstitial pneumonia - nonspecific interstitial pneumonitis

Volltext

Referenzen

References
1 Centers for Disease Control (CDC). Pneumocystis pneumonia—Los Angeles. MMWR Morb Mortal Wkly Rep 1981; 30 (21) 250-252
2 Petrosillo N, Pellicelli AM, Boumis E, Ippolito G. Clinical manifestation of HIV-related pulmonary hypertension. Ann N Y Acad Sci 2001; 946: 223-235
3 Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118 (4) 1133-1141
4 Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS 2008; 22 (Suppl. 03) S35-S40
5 Nunes H, Humbert M, Sitbon O , et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167 (10) 1433-1439
6 Opravil M, Pechère M, Speich R , et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997; 155 (3) 990-995
7 Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 1987; 18 (12) 1293-1296
8 Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991; 100 (5) 1268-1271
9 Sitbon O, Lascoux-Combe C, Delfraissy JF , et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177 (1) 108-113
10 Humbert M, Sitbon O, Chaouat A , et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173 (9) 1023-1030
11 Hsue PY, Deeks SG, Farah HH , et al. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 2008; 22 (7) 825-833
12 Mondy KE, Gottdiener J, Overton ET , et al; SUN Study Investigators. High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy. Clin Infect Dis 2011; 52 (3) 378-386
13 Chillo P, Bakari M, Lwakatare J. Echocardiographic diagnoses in HIV-infected patients presenting with cardiac symptoms at Muhimbili National Hospital in Dar es Salaam, Tanzania. Cardiovasc J Afr 2012; 23 (2) 90-97
14 Isasti G, Moreno T, Pérez I, Cabrera F, Palacios R, Santos J. High prevalence of pulmonary arterial hypertension in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses 2013; 29 (2) 231-234
15 Isasti G, Pérez I, Moreno T, Cabrera F, Palacios R, Santos J. Echocardiographic abnormalities and associated factors in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses 2013; 29 (1) 20-24
16 Quezada M, Martin-Carbonero L, Soriano V , et al. Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. AIDS 2012; 26 (11) 1387-1392
17 Rasoulinejad M, Moradmand Badie S, Salehi MR , et al. Echocardiographic assessment of systolic pulmonary arterial pressure in HIV-positive patients. Acta Med Iran 2014; 52 (11) 827-830
18 Crothers K. Chronic obstructive pulmonary disease in patients who have HIV infection. Clin Chest Med 2007; 28 (3) 575-587 , vi
19 Diaz PT, King MA, Pacht ER , et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000; 132 (5) 369-372
20 Morris A, Gingo MR, George MP , et al. Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era. AIDS 2012; 26 (6) 731-740
21 ten Freyhaus H, Vogel D, Lehmann C , et al. Echocardiographic screening for pulmonary arterial hypertension in HIV-positive patients. Infection 2014; 42 (4) 737-741
22 Selby VN, Scherzer R, Barnett CF , et al. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. AIDS 2012; 26 (15) 1967-1969
23 D'Alonzo GE, Barst RJ, Ayres SM , et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115 (5) 343-349
24 Simon MA. Right ventricular adaptation to pressure overload. Curr Opin Crit Care 2010; 16 (3) 237-243
25 Simon MA, Lacomis CD, George MP , et al. Isolated right ventricular dysfunction in patients with human immunodeficiency virus. J Card Fail 2014; 20 (6) 414-421
26 Lebech AM, Gerstoft J, Hesse B, Petersen CL, Kjaer A. Right and left ventricular cardiac function in a developed world population with human immunodeficiency virus studied with radionuclide ventriculography. Am Heart J 2004; 147 (3) 482-488
27 Dellegrottaglie S, García-Alvarez A, Guarini P, Perrone-Filardi P, Fuster V, Sanz J. Prevalence and severity of ventricular dysfunction in patients with HIV-related pulmonary arterial hypertension. Heart Lung 2014; 43 (3) 256-261
28 Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50 (25) 2357-2368
29 Secemsky EA, Scherzer R, Nitta E , et al. Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals. JACC Heart Fail 2015; 3 (8) 591-599
30 Gingo MR, Zhang Y, Ghebrehawariat KB , et al. Elevated NT-pro-brain natriuretic peptide level is independently associated with all-cause mortality in HIV-infected women in the early and recent HAART eras in the Women's Interagency HIV Study Cohort. PLoS One 2015; 10 (3) e0123389
31 Mette SA, Palevsky HI, Pietra GG , et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992; 145 (5) 1196-1200
32 Lund AK, Lucero J, Herbert L, Liu Y, Naik JS. Human immunodeficiency virus transgenic rats exhibit pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2011; 301 (3) L315-L326
33 Landi A, Iannucci V, Nuffel AV, Meuwissen P, Verhasselt B. One protein to rule them all: modulation of cell surface receptors and molecules by HIV Nef. Curr HIV Res 2011; 9 (7) 496-504
34 Marecki JC, Cool CD, Parr JE , et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 2006; 174 (4) 437-445
35 Sehgal PB, Mukhopadhyay S, Patel K , et al. Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques. Am J Physiol Lung Cell Mol Physiol 2009; 297 (4) L729-L737
36 Almodovar S, Hsue PY, Morelli J, Huang L, Flores SC ; Lung HIV Study. Pathogenesis of HIV-associated pulmonary hypertension: potential role of HIV-1 Nef. Proc Am Thorac Soc 2011; 8 (3) 308-312
37 Breuer S, Gerlach H, Kolaric B, Urbanke C, Opitz N, Geyer M. Biochemical indication for myristoylation-dependent conformational changes in HIV-1 Nef. Biochemistry 2006; 45 (7) 2339-2349
38 Poe JA, Smithgall TE. HIV-1 Nef dimerization is required for Nef-mediated receptor downregulation and viral replication. J Mol Biol 2009; 394 (2) 329-342
39 Briggs SD, Sharkey M, Stevenson M, Smithgall TE. SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1. J Biol Chem 1997; 272 (29) 17899-17902
40 Almodovar S, Knight R, Allshouse AA , et al. Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension. AIDS Res Hum Retroviruses 2012; 28 (6) 607-618
41 Wang T, Green LA, Gupta SK , et al. Transfer of intracellular HIV Nef to endothelium causes endothelial dysfunction. PLoS ONE 2014; 9 (3) e91063
42 Duffy P, Wang X, Lin PH, Yao Q, Chen C. HIV Nef protein causes endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells. J Surg Res 2009; 156 (2) 257-264
43 Dhillon NK, Li F, Xue B , et al. Effect of cocaine on human immunodeficiency virus-mediated pulmonary endothelial and smooth muscle dysfunction. Am J Respir Cell Mol Biol 2011; 45 (1) 40-52
44 Ensoli B, Buonaguro L, Barillari G , et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67 (1) 277-287
45 Barillari G, Ensoli B. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin Microbiol Rev 2002; 15 (2) 310-326
46 Dalvi P, Wang K, Mermis J , et al. HIV-1/cocaine induced oxidative stress disrupts tight junction protein-1 in human pulmonary microvascular endothelial cells: role of Ras/ERK1/2 pathway. PLoS ONE 2014; 9 (1) e85246
47 Dalvi P, O'Brien-Ladner A, Dhillon NK. Downregulation of bone morphogenetic protein receptor axis during HIV-1 and cocaine-mediated pulmonary smooth muscle hyperplasia: implications for HIV-related pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2013; 33 (11) 2585-2595
48 Ehrenreich H, Rieckmann P, Sinowatz F , et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 1993; 150 (10) 4601-4609
49 Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 2005; 333 (4) 1107-1115
50 Feijoo MQ, Toro R, López Vazquez de la Torre M , et al. Relationship between endothelin-1 levels and pulmonary arterial hypertension in HIV-infected patients. AIDS 2014; 28 (18) 2693-2699
51 Green LA, Kim C, Gupta SK, Rajashekhar G, Rehman J, Clauss M. Pentoxifylline reduces tumor necrosis factor-α and HIV-induced vascular endothelial activation. AIDS Res Hum Retroviruses 2012; 28 (10) 1207-1215
52 Mermis J, Gu H, Xue B , et al. Hypoxia-inducible factor-1 α/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling. Respir Res 2011; 12: 103
53 Hassoun PM, Mouthon L, Barberà JA , et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54 (1, Suppl): S10-S19
54 Perros F, Dorfmüller P, Montani D , et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 185 (3) 311-321
55 Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144 (2) 275-285
56 George MP, Champion HC, Simon M , et al. Physiologic changes in a nonhuman primate model of HIV-associated pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2013; 48 (3) 374-381
57 Parikh RV, Scherzer R, Nitta EM , et al. Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection. AIDS 2014; 28 (4) 511-519
58 Olivetta E, Percario Z, Fiorucci G , et al. HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kappa B activation. J Immunol 2003; 170 (4) 1716-1727
59 Dragic T, Litwin V, Allaway GP , et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381 (6584) 667-673
60 Ishida Y, Kimura A, Kuninaka Y , et al. Pivotal role of the CCL5/CCR5 interaction for recruitment of endothelial progenitor cells in mouse wound healing. J Clin Invest 2012; 122 (2) 711-721
61 Schecter AD, Calderon TM, Berman AB , et al. Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 2000; 275 (8) 5466-5471
62 Amsellem V, Lipskaia L, Abid S , et al. CCR5 as a treatment target in pulmonary arterial hypertension. Circulation 2014; 130 (11) 880-891
63 Cool CD, Rai PR, Yeager ME , et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003; 349 (12) 1113-1122
64 Montani D, Achouh L, Marcelin AG , et al. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. Eur Respir J 2005; 26 (5) 969-972
65 Gutiérrez F, Masiá M, Padilla S , et al. Occult lymphadenopathic Kaposi's sarcoma associated with severe pulmonary hypertension: A clinical hint about the potential role of HHV-8 in HIV-related pulmonary hypertension?. J Clin Virol 2006; 37 (2) 79-82
66 Bull TM, Meadows CA, Coldren CD , et al. Human herpesvirus-8 infection of primary pulmonary microvascular endothelial cells. Am J Respir Cell Mol Biol 2008; 39 (6) 706-716
67 Durrington HJ, Upton PD, Hoer S , et al. Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II. J Biol Chem 2010; 285 (48) 37641-37649
68 Montani D, Marcelin AG, Sitbon O, Calvez V, Simonneau G, Humbert M. Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. AIDS 2005; 19 (11) 1239-1240
69 Valmary S, Dorfmüller P, Montani D, Humbert M, Brousset P, Degano B. Human γ-herpesviruses Epstein-Barr virus and human herpesvirus-8 are not detected in the lungs of patients with severe pulmonary arterial hypertension. Chest 2011; 139 (6) 1310-1316
70 Huang L, Crothers K, Morris A , et al. Pneumocystis colonization in HIV-infected patients. J Eukaryot Microbiol 2003; 50 (Suppl): 616-617
71 Morris A, Sciurba FC, Lebedeva IP , et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 2004; 170 (4) 408-413
72 Swain SD, Han S, Harmsen A, Shampeny K, Harmsen AG. Pulmonary hypertension can be a sequela of prior Pneumocystis pneumonia. Am J Pathol 2007; 171 (3) 790-799
73 Morris A, Hillenbrand M, Finkelman M , et al. Serum (1→3)-β-D-glucan levels in HIV-infected individuals are associated with immunosuppression, inflammation, and cardiopulmonary function. J Acquir Immune Defic Syndr 2012; 61 (4) 462-468
74 Morse JH, Barst RJ, Itescu S , et al. Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med 1996; 153 (4 Pt 1): 1299-1301
75 Kopelman RG, Zolla-Pazner S. Association of human immunodeficiency virus infection and autoimmune phenomena. Am J Med 1988; 84 (1) 82-88
76 Spikes L, Dalvi P, Tawfik O , et al. Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine. Am J Respir Crit Care Med 2012; 185 (11) 1235-1243
77 Holmberg SD, Moorman AC, Williamson JM , et al; HIV Outpatient Study (HOPS) investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360 (9347) 1747-1748
78 Friis-Møller N, Reiss P, Sabin CA , et al; DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356 (17) 1723-1735
79 Frerichs FC, Dingemans KP, Brinkman K. Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. N Engl J Med 2002; 347 (23) 1895-1896
80 Domanski MJ, Sloas MM, Follmann DA , et al. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr 1995; 127 (1) 137-146
81 Tanuma J, Ishizaki A, Gatanaga H , et al. Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen. Clin Infect Dis 2003; 37 (7) e109-e111
82 Dhadwal AK, Wang X, Annambhotla S, Lin PH, Yao Q, Chen C. Capsaicin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine pulmonary arteries. Med Sci Monit 2009; 15 (1) BR1-BR5
83 Wang X, Chai H, Lin PH, Yao Q, Chen C. Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol 2009; 174 (3) 771-781
84 Zuber JP, Calmy A, Evison JM , et al; Swiss HIV Cohort Study Group. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004; 38 (8) 1178-1185
85 Degano B, Guillaume M, Savale L , et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010; 24 (1) 67-75
86 Torriani FJ, Komarow L, Parker RA , et al; ACTG 5152s Study Team. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52 (7) 569-576
87 George MP, Champion HC, Gladwin MT, Norris KA, Morris A. Injection drug use as a “second hit” in the pathogenesis of HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2012; 185 (11) 1144-1146
88 McLaughlin VV, Archer SL, Badesch DB , et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53 (17) 1573-1619
89 Galiè N, Corris PA, Frost A , et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62 (25, Suppl): D60-D72
90 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf . Accessed August 29, 2015.
91 Petitpretz P, Brenot F, Azarian R , et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89 (6) 2722-2727
92 Speich R, Jenni R, Opravil M, Jaccard R. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly 2001; 131 (45–46) 663-665
93 Barnier A, Frachon I, Dewilde J, Gut-Gobert C, Jobic Y, Leroyer C. Improvement of HIV-related pulmonary hypertension after the introduction of an antiretroviral therapy. Eur Respir J 2009; 34 (1) 277-278
94 Recusani F, Di Matteo A, Gambarin F, D'Armini A, Klersy C, Campana C. Clinical and therapeutical follow-up of HIV-associated pulmonary hypertension: prospective study of 10 patients. AIDS 2003; 17 (Suppl. 01) S88-S95
95 Sitbon O, Gressin V, Speich R , et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170 (11) 1212-1217
96 Barbaro G, Lucchini A, Pellicelli AM, Grisorio B, Giancaspro G, Barbarini G. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 2006; 92 (8) 1164-1166
97 Tcherakian C, Rivaud E, Zucman D, Metivier AC, Couderc LJ. Curing HIV-associated pulmonary arterial hypertension. Eur Respir J 2012; 39 (4) 1045-1046
98 Hardy H, Backman ES, Farber HW. Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension. Pharmacotherapy 2010; 30 (4) 139e-144e
99 Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002; 16 (11) 1568-1569
100 Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001; 15 (13) 1747-1748
101 Cicalini S, Chinello P, Grilli E, Petrosillo N. Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature. Curr HIV Res 2009; 7 (6) 589-596
102 Zona S, Santoro A, Besutti G , et al. Burden of subclinical heart and lung disease detected on thoracic CT scans of HIV patients on HAART. J Int AIDS Soc 2014; 17 (4) (Suppl. 03) 19716
103 Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150 (4) 967-972
104 Crothers K, Huang L, Goulet JL , et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 2011; 183 (3) 388-395
105 Jasmer RM, Edinburgh KJ, Thompson A , et al. Clinical and radiographic predictors of the etiology of pulmonary nodules in HIV-infected patients. Chest 2000; 117 (4) 1023-1030
106 Travis WD, Costabel U, Hansell DM , et al; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188 (6) 733-748
107 American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165 (2) 277-304
108 Centers for Disease Control (CDC). Revision of the case definition of acquired immunodeficiency syndrome for national reporting—United States. MMWR Morb Mortal Wkly Rep 1985; 34 (25) 373-375
109 Centers for Disease C. Prevention. Revised surveillance case definition for HIV infection–United States, 2014. MMWR Recomm Rep 2014; 63: 1-10
110 Oleske J, Minnefor A, Cooper Jr R , et al. Immune deficiency syndrome in children. JAMA 1983; 249 (17) 2345-2349
111 Morris JC, Rosen MJ, Marchevsky A, Teirstein AS. Lymphocytic interstitial pneumonia in patients at risk for the acquired immune deficiency syndrome. Chest 1987; 91 (1) 63-67
112 Tian X, Yi ES, Ryu JH. Lymphocytic interstitial pneumonia and other benign lymphoid disorders. Semin Respir Crit Care Med 2012; 33 (5) 450-461
113 van Zyl-Smit RN, Naidoo J, Wainwright H , et al. HIV associated Lymphocytic Interstitial Pneumonia: a clinical, histological and radiographic study from an HIV endemic resource-poor setting. BMC Pulm Med 2015; 15: 38
114 Teruya-Feldstein J, Temeck BK, Sloas MM , et al. Pulmonary malignant lymphoma of mucosa-associated lymphoid tissue (MALT) arising in a pediatric HIV-positive patient. Am J Surg Pathol 1995; 19 (3) 357-363
115 Resnick L, Pitchenik AE, Fisher E, Croney R. Detection of HTLV-III/LAV-specific IgG and antigen in bronchoalveolar lavage fluid from two patients with lymphocytic interstitial pneumonitis associated with AIDS-related complex. Am J Med 1987; 82 (3) 553-556
116 Ziza JM, Brun-Vezinet F, Venet A , et al. Lymphadenopathy-associated virus isolated from bronchoalveolar lavage fluid in AIDS-related complex with lymphoid interstitial pneumonitis. N Engl J Med 1985; 313 (3) 183
117 Chayt KJ, Harper ME, Marselle LM , et al. Detection of HTLV-III RNA in lungs of patients with AIDS and pulmonary involvement. JAMA 1986; 256 (17) 2356-2359
118 Dean NC, Golden JA, Evans LA , et al. Human immunodeficiency virus recovery from bronchoalveolar lavage fluid in patients with AIDS. Chest 1988; 93 (6) 1176-1179
119 Linnemann Jr CC, Baughman RP, Frame PT, Floyd R. Recovery of human immunodeficiency virus and detection of p24 antigen in bronchoalveolar lavage fluid from adult patients with AIDS. Chest 1989; 96 (1) 64-67
120 Andiman WA, Eastman R, Martin K , et al. Opportunistic lymphoproliferations associated with Epstein-Barr viral DNA in infants and children with AIDS. Lancet 1985; 2 (8469–8470) 1390-1393
121 Rubinstein A, Morecki R, Silverman B , et al. Pulmonary disease in children with acquired immune deficiency syndrome and AIDS-related complex. J Pediatr 1986; 108 (4) 498-503
122 Fackler JC, Nagel JE, Adler WH, Mildvan PT, Ambinder RF. Epstein-Barr virus infection in a child with acquired immunodeficiency syndrome. Am J Dis Child 1985; 139 (10) 1000-1004
123 Katz BZ, Berkman AB, Shapiro ED. Serologic evidence of active Epstein-Barr virus infection in Epstein-Barr virus-associated lymphoproliferative disorders of children with acquired immunodeficiency syndrome. J Pediatr 1992; 120 (2 Pt 1): 228-232
124 Lung ML, Lam WK, So SY, Lam WP, Chan KH, Ng MH. Evidence that respiratory tract is major reservoir for Epstein-Barr virus. Lancet 1985; 1 (8434) 889-892
125 Itescu S, Brancato LJ, Buxbaum J , et al. A diffuse infiltrative CD8 lymphocytosis syndrome in human immunodeficiency virus (HIV) infection: a host immune response associated with HLA-DR5. Ann Intern Med 1990; 112 (1) 3-10
126 Kazi S, Cohen PR, Williams F, Schempp R, Reveille JD. The diffuse infiltrative lymphocytosis syndrome. Clinical and immunogenetic features in 35 patients. AIDS 1996; 10 (4) 385-391
127 Helbert M, Stoneham C, Mitchell D, Pinching AJ. Zidovudine for lymphocytic interstitial pneumonitis in AIDS. Lancet 1987; 2 (8571) 1333
128 Scarborough M, Lishman S, Shaw P, Fakoya A, Miller RF. Lymphocytic interstitial pneumonitis in an HIV-infected adult: response to antiretroviral therapy. Int J STD AIDS 2000; 11 (2) 119-122
129 Dufour V, Wislez M, Bergot E, Mayaud C, Cadranel J. Improvement of symptomatic human immunodeficiency virus-related lymphoid interstitial pneumonia in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2003; 36 (10) e127-e130
130 Ognibene FP, Masur H, Rogers P , et al. Nonspecific interstitial pneumonitis without evidence of Pneumocystis carinii in asymptomatic patients infected with human immunodeficiency virus (HIV). Ann Intern Med 1988; 109 (11) 874-879
131 Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994; 18 (2) 136-147
132 Suffredini AF, Ognibene FP, Lack EE , et al. Nonspecific interstitial pneumonitis: a common cause of pulmonary disease in the acquired immunodeficiency syndrome. Ann Intern Med 1987; 107 (1) 7-13
133 Sattler F, Nichols L, Hirano L , et al. Nonspecific interstitial pneumonitis mimicking Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1997; 156 (3 Pt 1): 912-917
134 Griffiths MH, Miller RF, Semple SJ. Interstitial pneumonitis in patients infected with the human immunodeficiency virus. Thorax 1995; 50 (11) 1141-1146
135 Duggal L, Puri V, Vasdev N. Non-specific interstitial pneumonia in an HIV positive patient. J Assoc Physicians India 2005; 53: 564-565
136 Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15 (6) 311-320
137 Laing RB, Brettle RP, Leen CL. Venous thrombosis in HIV infection. Int J STD AIDS 1996; 7 (2) 82-85
138 Hasse B, Ledergerber B, Furrer H , et al; Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53 (11) 1130-1139
139 Bissuel F, Berruyer M, Causse X, Dechavanne M, Trepo C. Acquired protein S deficiency: correlation with advanced disease in HIV-1-infected patients. J Acquir Immune Defic Syndr 1992; 5 (5) 484-489
140 Feffer SE, Fox RL, Orsen MM, Harjai KJ, Glatt AE. Thrombotic tendencies and correlation with clinical status in patients infected with HIV. South Med J 1995; 88 (11) 1126-1130
141 Jong E, Louw S, van Gorp EC, Meijers JC, ten Cate H, Jacobson BF. The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. Thromb Haemost 2010; 104 (6) 1228-1234